Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4‐Year Follow‐Up

by Alessia Buglioni, Valentina Cannone, S. Jeson Sangaralingham, Denise M. Heublein, Christopher G. Scott, Kent R. Bailey, Richard J. Rodeheffer, Riccardo Sarzani, John C. Burnett Jr
Published 2015-12-01

CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart.

by Fernando L Martin, S Jeson Sangaralingham, Brenda K Huntley, Paul M McKie, Tomoko Ichiki, Horng H Chen, Josef Korinek, Gerald E Harders, John C Burnett
Published 2012-01-01

Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker

by Nicholas Y. Tan, MD, MS, Yihong Deng, PhD, Xiaoxi Yao, PhD, MPH, Lindsey R. Sangaralingham, MPH, Nilay D. Shah, PhD, Andrew D. Rule, MD, John C. Burnett, Jr., MD, Shannon M. Dunlay, MD, MS, S. Jeson Sangaralingham, MS, PhD
Published 2021-04-01